Clinical Biochemistry – Updates to Prostate Specific Antigen (PSA) ranges
Clinical Biochemistry – Updates to Prostate Specific Antigen (PSA) ranges
From Monday 2nd February the Clinical Biochemistry department will make a change to the reference ranges reported for the Prostate Specific Antigen (PSA) test. The updated ranges are based on those in the NICE CKS on Prostate Cancer [1] and are also in line with regional referral criteria for suspected prostate cancer.
|
Age (years) |
Current PSA upper reference limits (ug/L) |
NICE CKS referral guidance |
Proposed updated upper reference limits |
|
0 to 39 |
<2.5 |
Use clinical judgement |
No reported upper reference limit, but results >2.5 will be flagged in clinical systems |
|
40-49 |
<2.5 |
More than 2.5 |
2.5 |
|
50 to 59 |
<3.0 |
More than 3.5 |
3.5 |
|
60 to 69 |
<3.0 |
More than 4.5 |
4.5 |
|
70 to 79 |
<5.0 |
More than 6.5 |
6.5 |
|
80+ |
<10.0 |
More than 20 or more than 7.5 and there are symptoms suggestive of metastatic disease (bone pain and/or fatigue and/or significant unintended weight loss) |
7.5 |
If you would like any further information about this change, please contact the Clinical Biochemistry team by email (peh-tr.chemimm@nhs.net [2]).
